CLIMB Act: Cannabis Companies Could Soon Trade on NYSE and Nasdaq
Advertisement
Table of Contents
The Cannabis Industry's Wall Street Breakthrough: Understanding the CLIMB Act
For years, US cannabis companies have faced a peculiar Wall Street paradox: they operate in states where cannabis is legal and generate billions in revenue, yet they're banned from listing on the nation's largest stock exchanges. Instead, cannabis businesses have been relegated to over-the-counter markets, penny stocks, and Canadian exchanges—a financial arrangement that's hamstrung capital raising and limited investment opportunities for everyday Americans.
That could all change with the introduction of the CLIMB Act in March 2026.
What Is the CLIMB Act and Why Does It Matter?
The CLIMB Act (H.R. 7987), officially titled the Compassionate Licensing in Marijuana Banking Act, represents a watershed moment for cannabis finance. Introduced by Reps. Mike Reschenthaler (R-PA) and Earl Carter (D-LA)—a rare bipartisan pairing—this legislation directly addresses one of the cannabis industry's most persistent obstacles: access to traditional capital markets.
Currently, federal law creates an impossible situation for cannabis companies. Even in states where cannabis is fully legal and regulated, federal prohibition prevents these businesses from accessing the Securities and Exchange Commission's (SEC) mainboard listing processes. The result?
A thriving, multi-billion-dollar industry operating without the regulatory clarity that publicly-traded companies typically enjoy.
The CLIMB Act changes this by creating what's known as a "safe harbor"—legal protection that would allow major stock exchanges like the New York Stock Exchange (NYSE) and NASDAQ to list cannabis companies without fear of federal retaliation. It's a deceptively simple but powerful solution to a complex problem.
How the CLIMB Act Would Work: Breaking Down the Details
The bill's mechanism is straightforward but revolutionary. It provides explicit legal protection for exchanges and their affiliates, preventing federal agencies from:
- Revoking exchange licenses based on listing cannabis companies
- Imposing penalties or sanctions on exchanges or their personnel
- Restricting business operations as punishment for cannabis-related listings
- Pursuing criminal charges against employees who facilitate cannabis company listings
This safe harbor is critical because it removes the legal risk that has prevented exchanges from embracing the cannabis market. Currently, even though states like California, Colorado, and Illinois have legalized cannabis and generated significant tax revenue, these companies operate in what amounts to a federal gray zone when it comes to public markets.
The bill also extends protections to financial institutions and service providers that work with cannabis companies, addressing the broader banking crisis that has plagued the industry since federal prohibition remains technically in effect at the federal level.
The Cannabis Market's Capital Hunger: Why This Matters Now
The cannabis industry is mature. We're not talking about a niche market anymore. In 2025, the US cannabis market surpassed $35 billion in annual sales.
Yet despite this massive market size, cannabis companies remain starved for capital compared to other industries.
Consider the disparity:
- Traditional retail companies can access public capital markets, venture funding, and institutional investment
- Cannabis companies are limited to private equity, cannabis-specific funds, and OTC markets with restricted access
This capital constraint has real consequences. Cannabis businesses struggle to:
- Fund expansion into new states
- Invest in research and development
- Build infrastructure and supply chains
- Compete with larger, better-capitalized competitors
A cannabis company with access to NYSE or NASDAQ listing would fundamentally change this dynamic. Suddenly, these businesses could access trillions in institutional capital currently closed to them. Pension funds, mutual funds, index funds, and individual 401(k) investors—all currently prohibited from easy cannabis investment—would gain access to regulated cannabis company stocks.
The Bipartisan Coalition Building the Path Forward
What's particularly significant about the CLIMB Act is its bipartisan authorship. Rep. Reschenthaler (R-PA) and Rep.
Carter (D-LA) represent different constituencies and different political philosophies, yet they've united around a shared recognition that federal policy is out of step with state law and market reality.
This bipartisanship matters politically. Cannabis reform has often split along party lines, with Republicans worried about federal authority and Democrats concerned about social justice impacts. But the CLIMB Act frames the issue differently: as a matter of financial inclusion and states' rights.
That framing has already attracted support from unexpected quarters.
The coalition building around cannabis finance reform includes:
- Venture capital firms that have invested billions in cannabis but cannot execute public exits
- Financial institutions tired of the banking crisis and compliance nightmare
- Cannabis companies themselves desperate for legitimate capital access
- Conservative advocates who see federal overreach preventing state-legal businesses from operating normally
- Progressive advocates who recognize that restricting capital access to cannabis companies disproportionately impacts entrepreneurs of color
Comparing the CLIMB Act to Previous Cannabis Banking Reform Efforts
The cannabis industry has seen several attempts to address banking and finance issues. The SAFE Banking Act [Quick Definition: Federal bill that would let banks serve cannabis businesses without fear of prosecution], which has circulated Congress multiple times since 2013, focuses on allowing banks to service cannabis businesses. While important, SAFE Banking stops short of allowing public market access.
The CLIMB Act is different. It's not just about banking—it's about capital markets. It addresses a more fundamental question: can cannabis companies raise capital publicly in the United States?
Previous legislative attempts often foundered on concerns about federal overreach or maintaining drug war consistency. The CLIMB Act sidesteps these debates by focusing on the narrow but powerful issue of safe harbor protection for exchanges. It's a targeted, achievable solution rather than broad legalization.
What Stock Exchange Listing Would Mean for Cannabis Companies
For established cannabis companies currently trading on Canadian exchanges or OTC markets, NYSE or NASDAQ listing would represent transformational access to capital. Consider some implications:
Valuation Opportunities: Public market valuations for cannabis companies could reflect their true market potential rather than the discounts applied to OTC-traded securities.
Merger and Acquisition Activity: Cannabis companies could use publicly-traded stock as currency for acquisitions, enabling consolidation and growth that's currently difficult to execute.
Institutional Investment: Billions in institutional capital that's currently restricted from cannabis investment would become accessible, fundamentally reshaping the industry's capital structure.
International Expansion: With stronger capital access, cannabis companies could more easily expand internationally to markets like Canada, Germany, and Australia.
Research and Development: Currently underfunded cannabis research could accelerate with companies able to commit long-term capital to product development and clinical studies.
The Timeline: Where Things Stand in March 2026
Introduced in March 2026, the CLIMB Act is in the early stages of the legislative process. It's currently in committee, building support and momentum. The timeline for passage remains uncertain—cannabis reform often moves slowly through Congress—but the bill's introduction is significant itself.
What happens next typically includes:
- Committee hearings where industry experts, regulators, and policymakers testify
- Amendments and negotiations to build broader support
- Floor consideration in the House and Senate
- Executive signature if it successfully passes both chambers
Each step can take months or years, but the fact that this bill exists and has bipartisan sponsorship suggests momentum behind cannabis finance reform.
Concerns and Opposition to the CLIMB Act
Not everyone supports the CLIMB Act, and understanding the opposition helps contextualize the issue:
Law Enforcement Concerns: Some federal agencies worry that public market access would significantly expand cannabis industry funding and operation.
Public Health Arguments: Critics argue that facilitating cannabis industry expansion contradicts public health goals, though proponents counter that regulation through legal markets actually improves public health outcomes.
International Drug Control Treaties: The US is party to UN drug control conventions that complicate cannabis reform, though legal state-licensed cannabis increasingly challenges these international frameworks.
Market Volatility Concerns: Some regulators worry about including a federally-prohibited substance in mainstream stock markets, though the 2024-2025 stock market has functioned normally with state-legal cannabis companies operating successfully.
The Bigger Picture: Cannabis and American Federalism
At its core, the CLIMB Act debate reflects a fundamental tension in American federalism. States have legalized cannabis; the federal government maintains prohibition. In a federal system, something has to give.
The CLIMB Act chooses to resolve this tension not by changing federal law entirely, but by allowing states' legal cannabis markets to access the financial infrastructure needed to function effectively. It's a pragmatic solution that respects federalism while acknowledging market reality.
What This Means for Investors and Consumers
For potential cannabis investors: NYSE and NASDAQ listing would finally enable mainstream Americans to invest in cannabis companies through regular brokerage accounts, retirement accounts, and index funds. Currently, this is effectively impossible.
For cannabis consumers: Public company access to capital typically leads to lower prices, better products, and more competition. When industries can access growth capital, prices tend to decline as production scales up.
For cannabis workers: Cannabis companies with access to public capital can expand operations, create more jobs, and offer better compensation as they compete for talent in a more professional market.
Looking Forward: The CLIMB Act's Potential Legacy
If the CLIMB Act passes, it would represent the most significant cannabis industry finance reform since federal legalization debates began accelerating in the 2010s. It wouldn't legalize cannabis federally, but it would fundamentally change how cannabis businesses access capital.
The bill signals that even in a divided political landscape, there's pragmatic consensus emerging around cannabis finance reform. It suggests that future developments in cannabis policy may focus less on ideology and more on practical questions: how do we effectively regulate state-legal cannabis markets within a federal system?
Conclusion: A Watershed Moment for Cannabis Finance
The CLIMB Act isn't just legislation—it's a signal that American financial markets are ready to properly accommodate a legal, tax-generating, highly-regulated industry. For cannabis investors, entrepreneurs, and industry stakeholders, the March 2026 introduction of this bipartisan bill represents the most promising path yet to opening Wall Street's doors.
Whether the CLIMB Act ultimately passes will depend on Congressional dynamics and industry momentum through 2026 and beyond. But its very existence demonstrates that the debate around cannabis finance has evolved from "whether" to "how"—a crucial philosophical shift that could reshape the American cannabis industry for decades to come.
Pull-Quote Suggestions:
"In 2025, the US cannabis market surpassed $35 billion in annual sales."
"For years, US cannabis companies have faced a peculiar Wall Street paradox: they operate in states where cannabis is legal and generate billions in revenue, yet they're banned from listing on the nation's largest stock exchanges."
"A thriving, multi-billion-dollar industry operating without the regulatory clarity that publicly-traded companies typically enjoy."
Why It Matters: The CLIMB Act (H.R. 7987) could finally allow US cannabis companies to list on NYSE and Nasdaq. Learn what this bipartisan bill means for the industry.